Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+

Lung cancer is the most common form of cancer with the highest incidence worldwide. The mortality rates are highest in males and second highest in females, after breast cancer. The genetic predisposition to Non Small Cell Lung Cancer (NSCLC) is still under investigation, however, studies have shown...

Full description

Bibliographic Details
Main Author:	Viola Sacchi
Format:	Article
Language:	English
Published:	SEEd Medical Publishers 2011-06-01
Series:	Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:	gefitinib non small cell lung cancer epidermal growth factor receptor
Online Access:	https://journals.seedmedicalpublishers.com/index.php/FE/article/view/73

Similar Items

Research progress in the influence of EGFR genovariation on the clinical efficacy of gefitinib treatment of non-small cell lung cancer
by: Yang Wang, et al.
Published: (2018-02-01)

EGFR Gene Mutation Statuses in Advanced Non-small Cell Lung Cancer Patients and Their Influence on Effect of Gefitinib
by: Wei ZHONG, et al.
Published: (2012-09-01)

Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
by: Yung-Hung Luo, et al.
Published: (2015-09-01)

Correlation between DAPK Promoter Methylation and Gefitinib Sensitivity in Non-small Cell Lung Cancer
by: Weiqin Wu, et al.
Published: (2013-12-01)

Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib  in Patients with Non-small Cell Lung Cancer
by: Fei MA, et al.
Published: (2011-08-01)

The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
by: C.L. Watkins, et al.
Published: (2010-09-01)

Discrepancy between the Clinical Image and Pathological Findings of Non-Small Cell Lung Cancer Harboring an Epidermal Growth Factor Receptor Gene Mutation That Was Surgically Resected after Gefitinib Treatment
by: Yasuhiro Chikaishi, et al.
Published: (2014-02-01)

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
by: Bai H, et al.
Published: (2017-04-01)

How to Make the Choice in the Retreatment of EGFR-TKI for Advanced NSCLC Patients Who Benefited from Prior Gefitinib Therapy: the Original Drug or Switching to A Second EGFR-TKI?
by: Chuanhao TANG, et al.
Published: (2013-07-01)

Effect and Mechanism of Gefitinib Inhibition on Non-small Cell Lung Cancer  Radiosensitivity of HCC827 and H358 Cell Lines
by: Ziye GAO, et al.
Published: (2012-06-01)

A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients
by: Preenumol Thomas, et al.
Published: (2019-01-01)

FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer
by: Cuilan Sun, et al.
Published: (2020-08-01)

Pharmacokinetics of Gefitinib in a Patient with Non-Small Cell Lung Cancer Undergoing Continuous Ambulatory Peritoneal Dialysis
by: Teppei Yamaguchi, et al.
Published: (2015-02-01)

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death
by: Ping Chen, et al.
Published: (2019-06-01)

M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib‐resistant cell lines HCC827/GR
by: Fengqi Xiao, et al.
Published: (2020-11-01)

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?
by: Ajaz Bulbul, et al.
Published: (2018-04-01)

Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells
by: Haiying LI, et al.
Published: (2016-01-01)

Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1
by: Nakahara Y, et al.
Published: (2016-08-01)

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
by: Chih-Jen Yang, et al.
Published: (2017-05-01)

Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials
by: Ibrahim Ezzeldin
Published: (2010-01-01)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
by: Shang-Gin Wu, et al.
Published: (2020-09-01)

Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
by: Zhang L, et al.
Published: (2021-05-01)

Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation
by: Patel N, et al.
Published: (2017-06-01)

Multiple Myeloma Emerging after Prolonged Gefitinib Treatment for Non-Small Cell Lung Carcinoma
by: Sian Yik Lim, et al.
Published: (2011-04-01)

Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer
by: Vijay Patil, et al.
Published: (2019-01-01)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
by: Guo-Hao Xia, et al.
Published: (2014-12-01)

The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models
by: Silvia Ribback, et al.
Published: (2016-09-01)

Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment
by: Yang CJ, et al.
Published: (2016-03-01)

Gefitinib as First-line Therapy for Advanced or Metastatic Non-small Cell Lung Cancer Patients in Southern Taiwan
by: Cheng-Ta Yang, et al.
Published: (2010-01-01)

COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER
by: S. A. Protsenko, et al.
Published: (2017-01-01)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
by: Yuan Ying, et al.
Published: (2012-11-01)

LPIN1 Induces Gefitinib Resistance in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer Cells
by: Cho, J.H, et al.
Published: (2022)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
by: Sami Morin-Ben Abdallah, et al.
Published: (2017-05-01)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
by: Wang Wen-Ping, et al.
Published: (2012-01-01)

Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report
by: Genovefa Polychronidou, et al.
Published: (2013-03-01)

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
by: A. U. Kulikov
Published: (2015-03-01)

Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer
by: Thomas K. Sin, et al.
Published: (2016-02-01)

Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis
by: Zhu Jun, et al.
Published: (2013-01-01)

Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report
by: Duan H, et al.
Published: (2018-04-01)

Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer
by: Chi Pan, et al.
Published: (2016-09-01)

Cannot write session to /tmp/vufind_sessions/sess_7gfsklm4lhp8sltbr9sf0e0eao